PROSPEKTIF KOHORT SINGKAT STUDI PHAROS-HF TERHADAP INTERAKSI OBAT MAYOR PASIEN HEART FAILURE
DOI:
https://doi.org/10.47701/nwba8448Keywords:
Interaksi PK-PD resiko tinggi, Cohort Short Them, Pharos-HFAbstract
Heart Failure seringkali harus mengonsumsi banyak obat sekaligus. Kombinasi obat bisa menimbulkan efek interaksi hingga memperburuk kondisi pasien. Interaksi obat berisiko tinggi gagal jantung terjadi karena banyaknya regimen terapi. Penelitian bertujuan melihat demografi, tatalaksana mengikuti apakah ada dampak interaksi PK-PD resiko tinggi dengan outcome klinis dan kejadian readmisi pasca rawat inap 0-90 hari.
Metode penelitian menggunakan analisis observasi kohort singkat dengan studi Pharos-HF. Pharos-HF adalah registri prospektif yang dirancang untuk mempelajari demografi, tatalaksana, dan luaran outcome klinis pasien gagal jantung RS Akademik kota Surakarta. Interaksi obat di identifikasi menggunakan database (Medscape, Drug.com, Lexidrug).
Hasil populasi 89 pasien, masuk dalam kriteria inklusi interaksi 54 pasien. Interaksi obat Mayor dengan 2 outcome klinis (kreatinin, kalium) terhadap readmisi 30-60-90 hari mempunyai pengaruh yang signifikan P<0,05. Terjadinya Interaksi Obat PK-PD mayor dan outcome klinis (tekanan darah, ejeksi fraksi) terhadap kejadian readmisi 30-60-90 hari tidak memiliki pengaruh yang signifikan P>0,05 dengan nilai P lebih dari 0,05. Selain itu Interaksi farmakokinetika-farmakodinamika (PK-PD) obat mayor mempunyai peluang lebih besar terhadap kejadian Readmisi (Rehospitalisasi pada 0 – 90 hari pasca rawat inap) dengan nilai OR > 1 serta RR > 1.
References
Chang AR, Sang Y, Leddy J, et al. Antihypertensive medications and the prevalence of hyperkalemia in a large health system. Hypertension 2016;67:1181–8.
Drugs.com. 2024. https://www.drugs.com/interaction.
DiPiro, J. T., DiPiro, C.V., Wells, B. G., Schwinghammer, T. L. 2015. Pharmacotherapy Handbook. 9th ed. McGraw-Hill Education. United States.
[ESC] European Society of Cardiology. 2016. Guideline for the Diagnosis and Treatment of Acute and and Chronic Heart Failure.
Inaguma D, Koide S, Ito E, Takahashi K, Hayashi H, Hasegawa M, dkk. Rasio nitrogen urea darah terhadap kreatinin serum pada awal dialisis dikaitkan dengan mortalitas: Sebuah studi kohort prospektif multisenter. Clin. Exp. Nephrol. 2018;22(2):353–364. doi: 10.1007/s10157-017-1458-x. [ DOI ] [ PubMed ] [ Google Scholar ].
Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W and Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1-39 e14.
Lorga, A., Cunningham, C. M., Moazeni, S., et al. 2017. The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. Biology of Sex Differences, 8(1), 1–16. https://doi.org/10.1186/s13293-017-0152-8.
Maggioni AP, Anker SD, Dahlstrom U, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2013;15:1173–84.
McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA,Ponikowski P, Sabatine MS, Anand IS, B elohla´vek J, Bo¨ hm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Duka´t A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjo¨ strand M, Langkilde AM; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995–2008.
Nurkhalis, & Adista, R. J. 2020. Manifestasi Klinis dan Tatalaksana Gagal Jantung. Jurnal Kedokteran Nanggroe Medika 3(3): 36–46. https://doi.org/10.35324/jknamed.v3i3.106.
Orso F, Fabbri G and Maggioni AP. Epidemiology of Heart Failure. Handb Exp Pharmacol. 2017;243:15-33.
Perhimpunan Dokter Spesialis Kardiovaskuler Indonesia (PERKI). 2020. Pedoman Tatalaksana Gagal Jantung. Edisi kedua. PERKI. Indonesia.
Pusat Informasi Obat Nasional (PIONAS) BPOM RI. 2020 diakses 22 Juni 2024 dari http://pionas.pom.go.id/ ioni/lampiran-1-interaksi-obat.
Rajadurai J, Tse HF, Wang CH, Yang NI, Zhou J and Sim D. Understanding the Epidemiology of Heart Failure to Improve Management Practices: An Asia-Pacific Perspective. J Card Fail. 2017;23:327- 339.
Reyes EB, Ha JW, Firdaus I, Ghazi AM, Phrommintikul A, Sim D, Vu QN, Siu CW, Yin WH and Cowie MR. Heart failure across Asia: Same healthcare burden but differences in organization of care. Int J Cardiol. 2016;223:163-167.
Savarese G, Carrero JJ, Pitt B, et al. Factorsassociated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. Eur J Heart Fail 2018;20:1326–34.
Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF, Devore AD, Yancy CW and Fonarow GC. Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. J Am Coll Cardiol. 2017;70:2476-2486.
Siswanto B, Hersunarti N, Erwinanto, Barack R, Pratikto R, Nauli S and Lubis A. PEDOMAN TATALAKSANA GAGAL JANTUNG. PERHIMPUNAN DOKTERSPESIALIS KARDIOVASKULAR INDONESIA. 2015:48
Turana Y, Tengkawan J and Soenarta AA. Asian management of hypertension: Current status, home blood pressure, and specific concerns in Indonesia. J Clin Hypertens (Greenwich). 2020;22:483-485
Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: an update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guide- lines and the Heart Failure Society of America.J Am Coll Cardiol 2016;68:1476–88.
Ziaeian B and Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016;13:368-78.
